These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 15986288

  • 1. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis.
    Petersen-Benz C, Stiehl A.
    Z Gastroenterol; 2005 Jun; 43(6):587-90. PubMed ID: 15986288
    [Abstract] [Full Text] [Related]

  • 2. Primary sclerosing cholangitis: the role of endoscopic therapy.
    Stiehl A.
    Semin Liver Dis; 2006 Feb; 26(1):62-8. PubMed ID: 16496234
    [Abstract] [Full Text] [Related]

  • 3. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
    Tischendorf JJ, Krüger M, Trautwein C, Duckstein N, Schneider A, Manns MP, Meier PN.
    Endoscopy; 2006 Jul; 38(7):665-9. PubMed ID: 16673310
    [Abstract] [Full Text] [Related]

  • 4. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis.
    Murray MD, Burton FR, Di Bisceglie AM.
    J Clin Gastroenterol; 2007 Jan; 41(1):115-7. PubMed ID: 17198074
    [Abstract] [Full Text] [Related]

  • 5. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.
    Gotthardt DN, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A.
    Gastrointest Endosc; 2010 Mar; 71(3):527-34. PubMed ID: 20189511
    [Abstract] [Full Text] [Related]

  • 6. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH.
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [Abstract] [Full Text] [Related]

  • 7. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels.
    Furmanczyk PS, Grieco VS, Agoff SN.
    Am J Clin Pathol; 2005 Sep; 124(3):355-60. PubMed ID: 16191503
    [Abstract] [Full Text] [Related]

  • 8. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
    Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A.
    J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
    [Abstract] [Full Text] [Related]

  • 9. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
    Charatcharoenwitthaya P, Lindor KD.
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):32-6. PubMed ID: 17234554
    [No Abstract] [Full Text] [Related]

  • 10. Current diagnosis and management of primary sclerosing cholangitis.
    Tischendorf JJ, Geier A, Trautwein C.
    Liver Transpl; 2008 Jun; 14(6):735-46. PubMed ID: 18508363
    [Abstract] [Full Text] [Related]

  • 11. A retrospective single-center review of primary sclerosing cholangitis in children.
    Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N.
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):239-45. PubMed ID: 19121649
    [Abstract] [Full Text] [Related]

  • 12. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
    Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A.
    Cancer; 2004 Oct 01; 101(7):1609-15. PubMed ID: 15378479
    [Abstract] [Full Text] [Related]

  • 13. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.
    Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A.
    J Hepatol; 2009 Jul 01; 51(1):149-55. PubMed ID: 19410324
    [Abstract] [Full Text] [Related]

  • 14. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
    Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A.
    Eur J Gastroenterol Hepatol; 2007 Jun 01; 19(6):487-91. PubMed ID: 17489059
    [Abstract] [Full Text] [Related]

  • 15. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN.
    J Hepatol; 2013 Dec 01; 59(6):1278-84. PubMed ID: 23958938
    [Abstract] [Full Text] [Related]

  • 16. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.
    Barr Fritcher EG, Voss JS, Jenkins SM, Lingineni RK, Clayton AC, Roberts LR, Halling KC, Talwalkar JA, Gores GJ, Kipp BR.
    Cancer Cytopathol; 2013 Dec 01; 121(12):708-17. PubMed ID: 23839915
    [Abstract] [Full Text] [Related]

  • 17. [Primary sclerosing cholangitis is a premalignant condition].
    Schramm C, Galle PR.
    Z Gastroenterol; 2005 Jun 01; 43(6):607-11. PubMed ID: 15986292
    [Abstract] [Full Text] [Related]

  • 18. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.
    Turk J Gastroenterol; 2003 Sep 01; 14(3):181-4. PubMed ID: 14655062
    [Abstract] [Full Text] [Related]

  • 19. Recent insights in primary sclerosing cholangitis.
    Ponsioen CY.
    J Dig Dis; 2012 Jul 01; 13(7):337-41. PubMed ID: 22713082
    [Abstract] [Full Text] [Related]

  • 20. Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis.
    Gotthardt D, Stiehl A.
    Clin Liver Dis; 2010 May 01; 14(2):349-58. PubMed ID: 20682240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.